Treating Tardive Dyskinesia with Aripiprazole

Aripiprazole治療遲發性運動障礙

10.29478/TJP.200706.0009

何鎧任(Kellen Kai-Jen Ho)；劉亞平(Yia-Ping Liu)；江國棟(Kuo-Tung Chiang)

aripiprazole ； 遲發性運動障礙 ； 雙相性情感疾患 ； 多巴胺系統穩定劑 ； aripiprazole ； tardive dyskinesia ； bipolar disorder ； dopamine system stabilizer

台灣精神醫學

21卷2期（2007 / 06 / 01）

146 - 150

英文

目的：本文報告一位雙相性情感疾患之患者因出現遲發陸運動障礙(TD)，經使用aripiprazole治療後，發現有效改善症狀。個案報告：個案為48歲台灣男性，診斷為第一型雙相性情感疾患。經使用鋰鹽合併傳統型抗精神病藥物haloperidol治療15年左右，開始出現遲發性運動障礙。藥物轉換為第二代抗精神病藥物quetiapine後，症狀稍有改善。但TD症狀仍有持續，甚至有惡化情形。單一使用aripiprazole 10 mg/day後，TD症狀漸緩。結論：Aripiprazole因具有多巴胺部分到效劑效果，不會引起第二型多巴胺受體過度調節，推測可以藉由穩定多巴胺系統，防止TD惡化，除改善症狀外，進一步可能可以治療TD。

Objective: Tardive dyskinesia (TD) is a serious, potentially irreversible side-effect of the use of some antipsychotic medications for certain psychiatric patients. At time of writing, dopaminergic-receptor supersensitivity would appear to be the most-accepted hypothesis pertaining to the origin of this undesirable complication. Herein, we report on the case of a Taiwanese patient suffering from TD whose condition was improved with aripiprazole therapy. Case report: A 48-year-old Taiwanese man who was diagnosed as Bipolar I disorder had suffered from TD for several years after antipsychotic medication. This patient presented with persistent TD despite the treatment with atypical antipsychotic medication. Subsequent to aripiprazole having been administered to this patient, his TD improved substantially. Conclusion: This case suggests that aripiprazole's partial dopamine-agonist action may provide an alternative pharmacotherapy to the moreconventional means of treating TD.

1. Burris, KD,Molski, TF,Xu, C(2002).Aripiprazole a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.J Pharmacol Exp Ther,302,381-9.
2. Duggal, HS(2003).Aripiprazole-induced improvement in tardive dyskinesia.Can J Psychiatry,48,771-2.
3. Grant, MJ,Baldessarini, RJ(2005).Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole.Ann Pharmacother,39,1953.
4. Inoue, A,Miki, S,Seto, M(1997).Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum.Eur J Pharmacol,321,105-11.
5. Keck, P, Jr.,Calabrese, JR,McQuade, RD(2006).A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder.J Clin Psychiatry,67(4),626-37.
6. Liberman, JA(2004).Dopamine partial agonists: a new class of antipsychotic.CNS Drugs,18,251-67.
7. Margolese, HC,Chouinard, G,Kolivakis, TT,Beauclair, L,Miller, R,Annable, L(2005).Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.Can J Psychiatry,50,703-14.
8. McGavin, JK,Goa, KL(2002).Aripiprazole.CNS Drugs,16,779-86.
9. Sharma, A,Ramaswamy, S,Dewan, VK(2005).Resolution of ziprasidone-related tardive dyskinesia with switch to aripiprazole. Prim Care Companion.J Clin Psychiatry,7,36.
10. Witschy, JK,Winter, AS(2005).Improvement in tardive dyskinesia with aripiprazole use.Can J Psychiatry,50,188.

1. Pan, Yi-Ju,Lin, Yu-Ju,Chang, Shih-Cheng(2019).Covert Dyskinesia Associated with Aripiprazole: A Case Report.臺灣精神醫學,33(3),172-173.